Absci Corporation Common Stock H.C. Wainwright 28th Annual Global Investment Conference

Yeah. Perfect. Good afternoon, and thanks for joining us to have a conversation with Zach Jonasson, Chief Financial Officer and Chief Business Officer of Absci, and Alex Khan, Corporate Vice President and Head of IR at Absci.

Thanks, RK. Absci suddenly has changed its strategy, starting from a platform partnership story and now to a clinical stage company with three clinical stage programs and a wholly owned prolactin receptor franchise.

Yeah, absolutely. Again, thanks for having us. I've been involved with Absci since 2016. I used to manage a venture firm, so I've been a board member and now I'm in operations. I like to say I voted with my wallet and then with my feet. I can say it's a very exciting journey we're on. Our vision is to create a portfolio of DTC therapeutics that can be direct to consumer, leveraging telemedicine, and that can really be more oriented towards partnering with the consumer to improve their own health. Our first molecule, which we think will reach approval, is ABS-201 for pattern hair loss, which we think is a phenomenal market opportunity. There hasn't been innovation in that space for 30 years, and there's 80 million patients in the U.S. alone that have pattern hair loss, and they're very broadly dissatisfied with standard of care.

ABS-201 offers the kind of program that we really want to proselytize and invest in. It's a brand new category of therapy for a market that's desperate for solutions. Rather than an oral or topical you'd have to take daily with a lot of side effects and limited efficacy, this could be a product where you take two to three injections, kind of like a GLP-1, and you're set for multiple years of hair growth. So very convenient and durable, and that resonates very strongly with consumers. Our second program, as RK mentioned, is endometriosis. Another area where there's a fantastic, or unfortunately, a fantastic unmet medical need, where there's a really high patient burden. About 10% of women globally suffer with this disease. We think the timing for this program couldn't be better. You now have clinical guidelines for diagnosing endometriosis.

We think this program not only addresses a significant unmet need, but also could be brought to market as a DTC as well. Behind that, RK, we're using our platform, and I think you will probably have some questions around the platform, but we're using our platform today to generate additional programs that we think could fit into that broader strategy.

Yeah. I will start with the metrics. Those are metrics that we have succeeded on with our prior programs, ABS-201 as an example. We think we can do better, though. Today we are investing heavily in an entire agentic platform that interfaces with our AI models that design the antibodies. This agentic workflow involves disease biology, it involves selecting targets and selecting indications, and it plugs into or incorporates that AI design model or Origin model so that we can rapidly construct antibodies to different epitopes and commence testing those for POC. Our goal is to cut those timelines in half and cut those costs down even further, and we have a number of means of doing that. Part of that is leveraging the agentic platform we have built, which we have called Atlas.

Part of that is leveraging some of the things we are going to be doing in China for faster, cheaper clinical trial development.

Yeah. Let me comment on the PK, and I'll let Alex comment a little bit about what we're looking for at 13 weeks. We're very happy to see the PK profile, 65 days and counting. We think that that's going to enable at a minimum every two-month dosing, which is very convenient for patients. There's a potential upside to be something more like every three months. We'll see as we collect more data on PK as the trial moves forward. Think about the convenience factor for patients, and we've tested this in consumer studies. What they have today in standard of care is a daily application of minoxidil or finasteride, and if they stop, they lose their hair. Think about a product where you have maybe two injections over six months, and you don't have to worry about it for two years.